Drug Information

Drug General Information
Drug ID
D04QZV
Former ID
DIB001848
Drug Name
BHQ-880
Synonyms
BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis
Drug Type
Antibody
Indication Multiple myeloma [ICD9: 203; ICD10:C90] Phase 2 [523373]
Company
MorphoSys AG
Target and Pathway
Target(s) DKK1 protein Target Info [532792]
KEGG Pathway Wnt signaling pathway
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Wnt Signaling Pathway
FSH Signaling Pathway
Pathway Interaction Database Presenilin action in Notch and Wnt signaling
Wnt signaling network
Direct p53 effectors
Regulation of nuclear beta catenin signaling and target gene transcription
Validated targets of C-MYC transcriptional repression
Reactome TCF dependent signaling in response to WNT
Negative regulation of TCF-dependent signaling by WNT ligand antagonists
WikiPathways Mesodermal Commitment Pathway
Endoderm Differentiation
Differentiation Pathway
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Primary Focal Segmental Glomerulosclerosis FSGS
Cardiac Progenitor Differentiation
References
Ref 523373ClinicalTrials.gov (NCT01302886) Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma. U.S. National Institutes of Health.
Ref 532792Biological therapy for osteoporosis. Clin Calcium. 2014 Jun;24(6):919-25.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.